Semaglutide — the active ingredient in Ozempic, Wegovy, and compounded weight loss injectables — is one of the most effective medications ever developed for obesity and metabolic disease. To use it well and understand what you're putting in your body, you should understand how it actually works.
Here's the complete mechanism, explained clearly.
What Is a GLP-1 Receptor Agonist?
Your body naturally produces a peptide hormone called GLP-1 (glucagon-like peptide-1). It's secreted by L-cells in your small intestine in response to eating — particularly in response to carbohydrates and fats. It acts on GLP-1 receptors throughout your body.
Natural GLP-1's effects: - Stimulates the pancreas to release insulin (but only when blood glucose is elevated — a safety mechanism) - Suppresses glucagon (the hormone that raises blood sugar) - Slows gastric emptying — food stays in your stomach longer - Acts on the brain's appetite centers to signal fullness and reduce hunger - Has direct cardiovascular protective effects
The problem with natural GLP-1: it's broken down in the bloodstream within 2-3 minutes by an enzyme called DPP-4. It works as a short-signal hormone — a brief meal-time response, not a sustained regulator.
Semaglutide is a GLP-1 receptor agonist: a synthetic molecule designed to bind GLP-1 receptors with high affinity and resist DPP-4 breakdown. Its half-life is approximately 7 days — which is why it only needs to be injected once weekly. It creates sustained GLP-1 receptor activation rather than the brief post-meal pulse.
The Molecular Engineering
Semaglutide shares about 94% amino acid sequence similarity with human GLP-1. The key modifications that make it pharmacologically useful:
A substitution at position 8: Replaces alanine with aminoisobutyric acid, making it resistant to DPP-4 degradation. This is the primary change that extends its half-life from minutes to days.
Attachment to albumin via a fatty acid chain: Semaglutide has a C18 fatty diacid linker attached to lysine at position 26. This binds reversibly to albumin (the most abundant protein in blood), further protecting it from degradation and slowing renal clearance. The albumin binding is what makes the 7-day half-life achievable.
The result is a molecule that activates GLP-1 receptors continuously at steady-state levels, rather than the pulsatile post-meal signaling of natural GLP-1.
How Semaglutide Causes Weight Loss — The Actual Mechanisms
Weight loss from semaglutide comes from multiple simultaneous mechanisms:
1. Central appetite suppression
GLP-1 receptors are expressed in the hypothalamus, brainstem, and other brain regions that regulate appetite and food reward. Semaglutide crosses the blood-brain barrier (or acts via vagal nerve signaling) to directly reduce hunger signals.
The "food noise" effect — the persistent preoccupation with food that patients consistently report disappearing — is a central nervous system effect, not just "feeling full." Semaglutide reduces the hedonic (pleasure-seeking) drive to eat as well as the homeostatic hunger signal.
2. Slowed gastric emptying
Semaglutide acts on GLP-1 receptors in the stomach and GI tract to delay how quickly food moves from the stomach into the small intestine. This means: - Feeling full for longer after smaller meals - Reduced post-meal blood glucose spikes (slower glucose absorption) - Nausea as a side effect (the stomach emptying slowly produces discomfort, especially early in treatment)
3. Pancreatic effects (glucose-dependent insulin secretion)
Semaglutide enhances insulin secretion from beta cells in the pancreas — but only when blood glucose is elevated. This glucose-dependent mechanism is important: it means semaglutide doesn't cause hypoglycemia in non-diabetic individuals. When blood sugar is low, the insulin-stimulating effect is minimal.
4. Glucagon suppression
Glucagon is the counter-regulatory hormone to insulin — it raises blood glucose. Semaglutide suppresses glucagon secretion, reducing hepatic glucose output. This contributes to improved blood glucose control.
5. Adipose tissue effects
GLP-1 receptors are expressed in fat cells. Direct effects on adipose tissue include reduced fat storage signaling and possible enhancement of fat oxidation. This contributes to body composition changes beyond what caloric restriction alone would produce.
6. Cardiovascular effects
The SELECT trial (2023) demonstrated that semaglutide reduced major cardiovascular events by 20% in patients with pre-existing cardiovascular disease — effects independent of weight loss. Direct GLP-1 receptor activation in cardiac and vascular tissue reduces inflammation, improves endothelial function, and has direct cardioprotective signaling.
How Compounded Semaglutide Differs From Brand Name
Compounded semaglutide contains the same active molecule — semaglutide, as the free base or acetate salt. The peptide itself is chemically identical.
Differences from branded Ozempic/Wegovy: - Delivery format: Compounded versions typically come as multi-dose vials with separate syringes, versus the autoinjector pens used for brand-name products - Excipients: The inactive ingredients (stabilizers, diluents) may differ by compounding pharmacy - Manufacturing: Compounded preparations are made in smaller-batch FDA-registered compounding pharmacies under 503A or 503B regulations, rather than large pharmaceutical manufacturing facilities - Price: Compounded semaglutide is typically $200-400/month compared to $900-1,300+/month for branded versions
The clinical efficacy is driven by the peptide itself, not the delivery format. However, compounding pharmacy quality varies — which is why choosing a pharmacy that provides Certificate of Analysis documentation matters.
Tirzepatide: The Dual Receptor Version
Tirzepatide (Mounjaro, Zepbound) adds GIP receptor agonism to GLP-1 activation. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone involved in insulin secretion and metabolic regulation.
The dual mechanism appears to produce additive effects on weight loss — SURMOUNT-1 trials showed 20-22% average weight loss at maximum dose (15mg), compared to ~15% for semaglutide (2.4mg). The additional GIP agonism also appears to reduce GI side effects relative to pure GLP-1 agonism, though this varies individually.
Both are effective. Tirzepatide generally produces more weight loss; semaglutide may have better long-term cardiovascular data currently (more years of trial data).
Why GLP-1 Medications Work When Diets Don't
This is the fundamental question. If GLP-1 is just "suppressing appetite," why is it so much more effective than willpower-based restriction?
The answer is that obesity is a neuroendocrine disease, not a character flaw. The brain's setpoint system actively defends excess body weight using hunger signals, metabolic adaptation, and food reward circuits. Willpower-based restriction fights against this system directly — and loses, consistently, in the long run.
GLP-1 medications act directly on the neurobiological mechanisms that regulate the setpoint. They don't suppress appetite by fighting your biology — they change the signals your brain is receiving so that a lower body weight becomes the defended normal.
This is why the weight regain data after stopping GLP-1 is sobering: the setpoint drifts back up when the medication is discontinued. It's not that the drug "stops working" — the underlying disease reasserts itself.
[Start GLP-1 treatment at Marrow](/start) — physician consultation, compounded semaglutide or tirzepatide, ongoing support.
Frequently Asked Questions
What is semaglutide and how does it cause weight loss?
Semaglutide is a GLP-1 receptor agonist — a synthetic version of a natural gut hormone that regulates hunger. It reduces appetite by acting on the brain's appetite centers, slows gastric emptying, improves insulin signaling, and suppresses glucagon. The combined effect produces sustained caloric reduction without the hunger rebound of traditional dieting.
Is compounded semaglutide the same as Ozempic?
The active molecule is the same — semaglutide peptide. Compounded versions come in vials with syringes rather than autoinjector pens, and are manufactured in compounding pharmacies at a fraction of the branded price. Quality varies by pharmacy — look for pharmacies that provide Certificate of Analysis documentation.
Why does semaglutide only need to be injected once a week?
Semaglutide is engineered to resist the enzyme (DPP-4) that breaks down natural GLP-1 in minutes. A fatty acid linker binds it to albumin in the bloodstream, further extending its half-life to approximately 7 days. This allows once-weekly dosing at steady-state blood levels.
Does semaglutide cause low blood sugar?
In non-diabetic patients, semaglutide rarely causes hypoglycemia. Its insulin-stimulating effect is glucose-dependent — it only enhances insulin secretion when blood sugar is elevated. When blood sugar is normal or low, the insulin-stimulating effect is minimal, making hypoglycemia rare outside of combination with other diabetes medications.
Why do people regain weight after stopping semaglutide?
Obesity is a chronic neuroendocrine condition — the brain's setpoint system defends excess weight through hunger and metabolic adaptation. Semaglutide treats the underlying signaling; when discontinued, the setpoint reverts and hunger returns. Long-term use or structured maintenance is often necessary to sustain results.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
